Active ingredients:

Pramipexole 0.25 mg or 1.0 mg.

PRAMIPEXOLE is a dopamine agonist that binds with high selectivity and specificity to the D2 subfamily of dopamine receptors of which it has a preferential affinity to D3 receptors (it is well distributed in the mesolimbic area), and has full intrinsic activity. While PRAMIPEXOLE has affinity to D3 receptors, it has low affinity to α2-adrenergic receptors and very low or undetectable affinity to other dopaminergic, adrenergic, histaminergic, adenosine and benzodiazepine receptors. Pramipexole alleviates parkinsonian motor deficits by stimulation of dopamine receptors in the striatum. Animal studies have shown that pramipexole inhibits dopamine synthesis, release, and turnover. The ability of pramipexole to alleviate the signs and symptoms of Parkinson's disease is believed to be related to its ability to stimulate dopamine receptors in the striatum. This assumption is supported by a dose-dependent antagonism of Parkinsonian symptoms in rhesus monkeys pretreated with the neurotoxin N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) which destroys dopamine cell bodies in the substantia nigra.

Indications

• used for the treatment of the signs;
• symptoms of idiopathic Parkinson's disease.

Dosage and pharmaceutical form:

tablets 0.25 mg or 1.0 mg, 10 tablets in blister, 3 blisters in package.